Managing on-target, off-tumor toxicity involves several strategies:
Biomarker Identification: Identifying biomarkers that predict toxicity can help personalize treatment plans, allowing for dose adjustments or alternative therapies. Combination Therapy: Combining targeted therapies with drugs that mitigate specific side effects can enhance efficacy while minimizing toxicity. For example, corticosteroids are often used to manage immune-related adverse events from checkpoint inhibitors. Monitoring and Early Intervention: Regular monitoring of patients for early signs of toxicity allows for prompt intervention, potentially preventing severe complications. This can involve routine blood tests, imaging studies, and clinical assessments. Drug Modification: Developing next-generation drugs that are more selective for cancer cells or engineering delivery systems that target tumors more precisely can reduce off-tumor effects.
